Hematology

Patients with heavily pretreated lymphoma experienced promising clinical responses following treatment with the innate cell engager AMF13 plus preactivated and expanded natural killers (NK) cells.

A new method of developing CAR T-cell products produced infusion-ready cells in under 24 hours.

Axicabtagene ciloleucel is now FDA-approved for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

Investigators are seeking to overcome barriers to help patients with acute myeloid leukemia achieve complete and durable remissions by focusing their attention on novel agents engineered to target adhesion factors.

The disparate use in telemedicine between White and Black patients warrants further exploration into compound cases, such as economic and societal factors.

Investigators hope that the novel obecabtagene autoleucel, a second-generation CAR T-cell therapy may fill an unmet need by representing a durable treatment option for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Duvelisib, a dual PI3K-δ,γ inhibitor, is now listed as a category 2A designated option for second-line and subsequent treatment of patients with relapsed/refractory peripheral T-cell lymphoma in the National Comprehensive Cancer Network Clinical Practice Guidelines.

The FDA has granted a priority review designation of ivosidenib plus azacitidine on the indication of previously untreated IDH1-mutated acute myeloid leukemia.

A proactive, multidisciplinary approach is the best way to address belantamab mafodotin—related keratopathy in patients with multiple myeloma.

An expert with Moffitt Cancer Center comments on the ongoing FELIX trial, and the potential of the novel CAR T-cell therapy, obecabtagene autoleucel, to change the B-cell acute lymphoblastic leukemia treatment paradigm.

The FDA has approved pacritinib for patients with cytopenic myelofibrosis and severe thrombocytopenia.

Newly FDA-approved ciltacabtagene autoleucel was found to induce an objective response rate of 98% in patients with relapsed/refractory multiple myeloma.

The FDA set the Under the Prescription Drug User Fee Act date for June 24, 2022.

Oral Bruton tyrosine kinase inhibitors make notable strides in CLL treatment. Chimeric antigen receptor T-cell therapy continues to command attention by besting standard-of-care therapies.

An expert with Oregon Health & Science University discusses whether Orca-T graft can fulfill an unmet need in the field of allogeneic stem cell transplantation for myelofibrosis.

Frontline treatment with brentuximab vedotin and chemotherapy yielded superior survival outcomes in patients with advanced classical Hodgkin lymphoma.

In this episode of “The Vitals,” Dr. Janice Post-White discusses how she balanced working as an oncology nurse through her child’s cancer diagnosis, and the lessons she learned from the experience.

The FDA has expanded the prescribing information for axicabtagene ciloleucel to include prophylactic corticosteroids for all approved indications.

Ibrutinib plus rituximab is effective, easy to administer, and removes the need for chemotherapy in older patients, say experts.

Oral decitabine, an oral fixed-dose of combination decitabine and CDA inhibitor cedazuridine, is an FDA-approved therapy for patients with lower-risk myelodysplastic syndromes.

Recently presented findings demonstrate that aspacytarabine may represent a viable treatment option for various subsets of patients with acute myeloid leukemia.

An expert from Mount Sinai Hospital comments on potential new ruxolitinib combinations to treat patients with myelofibrosis and MPNs.

An expert from the Tisch Cancer Institute highlights the importance of medication adherence, nausea management, and proper hydration for patients being treated with selinexor for relapsed or refractory multiple myeloma.

A comparative analysis indicated that lisocabtagene maraleucel generated superior quality of life in patients with relapsed/refractory large B-cell lymphoma compared with the current standard of care.

Kathy Burns, MS, APRN-CNS, AGCNS-BC, of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, comments on the importance of self-awareness as an oncology nurse when working to overcome one’s implicit bias.